Abstract
This chapter reviews clinical studies focusing on treatment of various diseases with rituximab and its toxic side effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.
Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematologic side effects following rituximab therapy in children. Haematologica. 2006;91(8 Suppl):ECR36.
Chaiwatanatorn K, Lee N, Griqq A, Filshie K, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121(6):913–8.
Tesfa D, Glins T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia arrest at the (pro)mylocyte stage of granulopoisis. Med Oncol. 2008;25(4):374–9.
Otrock ZK, Mahfouz RA, Oghlahian GO, Salem ZM, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica. 2005;90(Suppl):ECR23.
Leo E, Scheuer L, Schmidt-Wolf IG, Kerowgan M, Schmitt C, Leo A, et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur J Haematol. 2004;73(4):251–7.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Mohammad Beigi, P.K. (2018). Literature Review. In: A Clinician's Guide to Pemphigus Vulgaris. Springer, Cham. https://doi.org/10.1007/978-3-319-67759-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-67759-0_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67758-3
Online ISBN: 978-3-319-67759-0
eBook Packages: MedicineMedicine (R0)